Incyte Corporation (NASDAQ: INCY) is on The StockGuru Leader Board today. The stock is up as much as 11.75% on Thursday.
Volume traded – so far – as this release was issued intraday: 5,728,746
Join in on the Discussion about INCY: http://members.stockguru.com/stocks/incy/
About the Company:
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation. The company offers JAKAFI, an oral janus associated kinase inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. The companys product pipe line includes INCB18424, which is in Phase III clinical trial for polycythemia vera; Phase II trial for essential thrombocythemia; Phase II trial for pancreatic cancer; Phase I/II trial to treat solid tumors/other hematologic malignancies. The companys products in pipeline also comprise INCB28050 that is in Phase IIb clinical trail for the treatment rheumatoid arthritis and psoriasis; INCB28060 and INCB24360, which are Phase I clinical trial products for the treatment of solid tumors. It has a collaborative research and license agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; and Pfizer Inc. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
About the StockGuru Leader Board:
We watch for stocks moving up and creating a positive momentum in the market. We are not compensated for coverage.
Feel free to suggest a stock for coverage if you see it breaking out. Contact: [email protected].
StockGuru.com
StockGuruCanada.com
Shareholdervision.com
BoldStocks.com
IR Affiliates – IRIR.co
StoneBridge Web & SEO – StonebridgeIQ.com
All content on StockGuru.com is original content – with the exception of client news releases. All content is (C) Copyright 2002 to 2012 StockGuru. No content may be used in whole or in part without the express written consent of our Publisher. We encourage web sites interested in our content to offer a reciprocal exchange agreement in exchange for use of some of our content. We do not offer advance approval, but contact our Publisher if you have an interest in repropagating our content. Contact as at: [email protected] or (469) 252-3030. Mailing address: 1601 Berwick Drive; McKinney, Texas 75070